FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] GALA RENEE D					2. Issuer Name and Ticker or Trading Symbol <u>Theravance Biopharma, Inc.</u> [TBPH]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O THERAVANCE BIOPHARMA US, INC.				3. Date of Earliest Transaction (Month/Day/Year) 06/03/2014									х	Office below	r (give title) VP-Fi	nan	Other (below)	specify	
901 GATEWAY BLVD					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) SOUTH SAN FRANCISCO CA 94080													X	Form f	Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State) (Zip)																		
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day					Execution Dat			3. Transacti Code (Ins) 8)							ties For cially (D) I Ind		n: Direct	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amoun	ount (A) or (D)		ice	Reporte Transa	Reported Transaction(s) (Instr. 3 and 4)		1. 4)	(1150.4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transactior Code (Instr 8)		on of I		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		o D S (I	. Price f erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
				c	Code	v	(A)	(D)	Date Exercisable		piration te	Title	Amou or Numb of Shares	er					
Stock Option (Right to Buy)	\$23.51	06/03/2014			A		85,000		(1)	06	/02/2024	Common Stock	85,00	00	\$0	85,000		D	

Explanation of Responses:

1. This option shall vest and become exercisable as follows: (a) with respect to the first 25% of the Company's shares subject to the option on February 20, 2015, subject to the optioned's continuous service through such date and (b) with respect to an additional 1/48th of the Company's shares subject to the option when the optione completes each month of continuous service thereafter. The option shall be fully vested and exercisable on February 20, 2018 provided the optionee remains in continuous service with the Company through such date.

Brett A. Grimaud, Attorney-in-06/05/2014

Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.